|
|
Asthma and Allergy News
Montelukast (Singulair®) and Zafirlukast (Accolate®): new asthma treatments
Montelukast: what is it?
Singulair® (Montelukast), launched in the UK in February 1998, is a
new once daily tablet treatment for asthma. There is a chewable tablet for
children aged 6 to 15 years.
Together with zafirlukast, it is new kind of treatment for asthma, and works by
blocking the effect of substances called leukotrienes, which are important in
asthma.
Montelukast is an add-on treatment which improves the health of people with
asthma who are already using inhaled steroid 'preventer' treatments but are not
getting enough help from those and the other usual treatments.
How does montelukast work? Montelukast is one of a group of new drugs
which work by blocking the effect of an important group of substances released in
the lungs during the process which leads to asthma. These substances are called
leukotrienes. Just as antihistamines stop a substance called histamine from
working, so montelukast stops leukotrienes from working.
Leukotrienes are important in asthma because their release from cells in the
lungs causes narrowing of the air passages, for example by making the muscles
around the air tubes contract. So one benefit of montelukast is that it acts
against this muscle contraction, and so against narrowing of the air passages.
But leukotrienes act in quite a number of ways to help produce asthma. We now
know that in asthma the air tubes are not just narrowed by contracting muscle
fibres, but that the lining membrane of the air tubes is inflamed, looking red in
colour. The microscope shows that the inflamed lining membrane is also full of
cells we normally think of as white blood cells,
including cells called eosinophils. Over the longer
run these cells cause damage in the lungs, which is why older people with asthma
generally don't get such good results from treatment as younger people.
Leukotrienes play an important part in bringing about this inflammation, and
montelukast should help alsthma in the longer term by helping to minimise
inflammation and the damage it causes.
How well does it work in practice? Careful trials on large numbers of
patients showed that, in some groups of people with asthma, montelukast reduced
night-time asthma attacks as well as attacks and poor control during the daytime.
Regular use also reduced the number of times people needed to use steroid tablets
because the asthma went out of control.
Some people claim that montelukast may be specially useful for some kinds of
asthma, such as asthma brought on by exercise or by aspirin.
Time will tell how much montelukast will contribute to the life of people who
have asthma. It seems that we are not looking at a dramatic cure, but at a
medicine which will make a very positive difference for many people.
Who makes it? Merck Sharp & Dohme Ltd.
How expensive is it? In the UK, montelukast costs just over £1 per day. Like many other athma treatments it is not cheap. But
lives harmed by asthma are not cheap either.
Top of page - Table of Contents
European Allergy Congress, Rhodes, June 1997 European
Academy of Allergy and Clinical Immunology
Allergy specialists from all over the world attended the annual meeting of the
European Academy. Drug companies with new medicines to present were Zeneca (the
former ICI Pharmaceuticals) with Accolate, a new tablet for asthma, and
Hoechst Marion Roussel with Telfast
(fexofenadine, in USA Allegra), a new antihistamine described in our
section on these treatments.
Accolate is one of a set of new asthma medicines which block the effect of
subtances called 'leukotrienes' which are released in the lungs during asthma,
playing a large part in producing the symptoms of asthma (Singulair , official name montelukast, also belongs to this group). Just how useful
Accolate will be for most patients with asthma remains to be seen. One hope is
that it will turn out to be particularly helpful for patients with asthma which
is caused by aspirin and similar substances. Such asthma is commoner than most
doctors think, and the treatment does need to be different from other kinds of
asthma. Despite astonishing advances in asthma treatment over the last thirty
years, the results are not all we would wish, and a totally new type of treatment
is welcome. There are several other drugs in development or in the process of
becoming available which interfere with the production or effect of
leukotrienes.
Can you make your asthma better by getting your nose treated? Several lecturers spoke about this, and they produced evidence that indeed you can. Lots of people with asthma have allergy affecting their noses, but this usually does not get much attention because all the time with the doctor or asthma nurse is spent on the asthma. A bit of time and treatment devoted to the nose could make a lot of people a lot happier and, it seems, make their asthma better as well.
The reason is probably that if your nose functions well it acts as an efficient filter, removing allergy-producing dust and pollutants and stopping them from getting to your lungs.
So remember to tell the doctor about your nose as well as about your asthma.
Top of page - Table of Contents
Latex allergy has been the subject of a lot of research. Latex allergy is a serious condition of health care workers, mainly nurses, and of children and other people who have a lot of surgery or other treatment involving latex gloves and catheters. Part of the research consisted of doing blood and skin tests, with surprisingly high percentages of positive results. What was often not clear was how many of the people with positive results would really have a dangerous reaction if they came into contact with latex.
Terfenadine. Is it safe?
This obsolete antihistamine may still be found in some medicine cabinets and nooks and crannies. It should be destroyed.
Top of page - Table of Contents
If you are allergic to peanuts, Is peanut oil dangerous?
British Medical Journal 12 April 1997.
Good news from the research team in Southampton, at the University Department of Child Health. This team has done more research on nut allergy than any other group in Britain. They have now tested peanut oil on people with peanut allergy more thoroughly than anyone else. They gave 62 adults with peanut allergy refined peanut oil, up to 10 ml. None of the volunteers had allergic reactions to refined peanut oil.
But crude unrefined peanut oil did cause reactions in 6 out of the 62 peanut allergic volunteers. These reactions were not severe, but clearly people with nut allergy must avoid such oils.
The team write that products should be labelled so that crude unrefined oil, which is potentially dangerous, can be distinguished from refined oil, which seems to be safe. Who could argue with that?
Some 'gourmet oils' have had peanut material added to provide a peanut flavour; these are obviously dangerous if you are allergic to peanut.
COMMENT:
Although the refined oils did not cause dangerous reactions, this may not quite be the whole story. Theoretically it is possible that traces of peanut protein which cannot cause a reaction would nevertheless sensitise someone, or increase the sensitivity of someone who is already allergic. To find out if this happens, a quite separate research project would be needed, but this might not be possible. We recommend that if you are allergic to peanuts you should avoid any peanut oil if possible, but not get too worried if you make a mistake about refined peanut oil. The advice is an attempt to play safe, just in case undetectable traces of protein in refined oil can increase allergy. We emphasise, this is a theoretical point with no practical evidence to support it. All the evidence is that refined peanut oil does not cause dangerous reactions.
Click here to go to section on peanut oil in the nut allergy page.
Top of page - Table of Contents
Suggestions or requests for information will be of great interest to us. Whether we can respond will depend on pressure of work, not willingness. Use the Guest Book to pass your questions to us.
This page is maintained by Martin Stern.
Its last update was on 8 Dec 2000. Reference to terfenadine curtailed 31 July 2003.
Copyright © 1997, 1998, 2000 M. A. Stern
|